As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 03, 2026 at 3:00 PM to consider, among others, annual audited financial statements of the Company for the year ended June 30, 2026.

(Q3 Un-audited): EPS was Tk. 6.11 for January-March 2026 as against Tk. 4.45 for January-March 2025; EPS was Tk. 20.20 for July 2025-March 2026 as against Tk. 15.77 for July 2024-March 2025. NOCFPS was Tk. 13.00 for July 2025-March 2026 as against Tk. 5.58 for July 2024-March 2025. NAV per share was Tk. 155.55 as on March 31, 2026 and Tk. 138.58 as on June 30, 2025. Reasons for deviation: EPS has increased compared to previous year's 3rd quarter due to increase in sales, resulting from expansion of production capacity. NOCFPS increased due to increase in collection. NAVPS increased due to increase in retained earnings.

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2026 at 3:00 pm to consider, among others, Un-Audited Financial Statements for the Third Quarter (Q3) period ended March 31, 2026.

The Company has informed that 149,500 shares held by Late M. A. Masud, a Sponsor Director and former Chairman of the Company, who passed away on 11.11.2025, will be transmitted among his successors in accordance with the Succession Certificate issued by the Honorable Court. The names of the successors, their relationships with the deceased shareholder, and the number of shares to be received by each successor are as follows: 1. Mrs. Shahinoor Baby, Wife, Sponsor Director and Chairman of the Company, will receive 18,688 shares; 2. Mr. Md. Nurul Mahbub, Son, will receive 52,325 shares; 3. Mrs. Farzina Binty Masud, Daughter, will receive 26,162 shares; and 4. Mr. Mahir Musleh, Son, will receive 52,325 shares.

The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2025 to the respective shareholders.

(Q2 Un-audited): EPS was Tk. 7.28 for October-December 2025 as against Tk. 5.66 for October-December 2024; EPS was Tk. 14.09 for July-December 2025 as against Tk. 11.32 for July-December 2024. NOCFPS was Tk. 10.11 for July-December 2025 as against Tk. 4.93 for July-December 2024. NAV per share was Tk. 149.54 as on December 31, 2025 and Tk. 138.58 as on June 30, 2025. Reasons for deviation: EPS has increased compared to previous year's 2nd quarter mostly due to increase in sales, resulting from expansion of production capacity. NOCFPS increased due to increase in collection. NAV has increased due to increase in retained earnings.

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 29, 2026 at 3:00 PM to consider, among others, Un-Audited Financial Statements for the Second Quarter (Q2) period ended December 31, 2025.

National Credit Ratings Limited (NCR) has assigned the rating of the Company as "A" in the long term and "ST-2" in the short term along with Stable outlook based on audited financial statements as on June 30, 2025.

The auditor of the company has given the Emphasis of Matters paragraph in the audited financial statement for the year ended on 30 June 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/Pharma%20Aids%20Limited_2025.pdf

Trading of the shares of the company will resume on 08.12.2025.